Kellie L. Jones

489 total citations
13 papers, 364 citations indexed

About

Kellie L. Jones is a scholar working on Oncology, Complementary and alternative medicine and Pharmacology. According to data from OpenAlex, Kellie L. Jones has authored 13 papers receiving a total of 364 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 3 papers in Complementary and alternative medicine and 2 papers in Pharmacology. Recurrent topics in Kellie L. Jones's work include Cancer Treatment and Pharmacology (4 papers), HER2/EGFR in Cancer Research (3 papers) and Complementary and Alternative Medicine Studies (3 papers). Kellie L. Jones is often cited by papers focused on Cancer Treatment and Pharmacology (4 papers), HER2/EGFR in Cancer Research (3 papers) and Complementary and Alternative Medicine Studies (3 papers). Kellie L. Jones collaborates with scholars based in United States. Kellie L. Jones's co-authors include Aman U. Buzdar, Laura Boehnke Michaud, Diane C. Bodurka, Karen Basen‐Engquist, Gabriel N. Hortobágyi, J. Lynn Palmer, John J. Kavanagh, Judith A. Smith, Vicente Valero and Janet L. Espirito and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Kellie L. Jones

13 papers receiving 357 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kellie L. Jones United States 8 151 137 72 59 53 13 364
Elizabeth L. Kaufman United States 5 105 0.7× 51 0.4× 20 0.3× 20 0.3× 166 3.1× 6 427
Bekir Öztürk Türkiye 12 122 0.8× 26 0.2× 53 0.7× 17 0.3× 21 0.4× 27 351
N. Lee United States 12 141 0.9× 94 0.7× 142 2.0× 29 0.5× 36 0.7× 51 563
Yuan Zhuang China 12 66 0.4× 41 0.3× 153 2.1× 26 0.4× 13 0.2× 43 366
Audrey Jung Germany 13 167 1.1× 18 0.1× 97 1.3× 6 0.1× 42 0.8× 30 367
Myles Spar United States 5 136 0.9× 46 0.3× 109 1.5× 6 0.1× 9 0.2× 8 451
Whitney Lieb United States 6 67 0.4× 78 0.6× 73 1.0× 8 0.1× 6 0.1× 13 260
Pierre Del Vecchio Canada 6 59 0.4× 30 0.2× 58 0.8× 10 0.2× 10 0.2× 10 272
Huiyan Niu China 15 95 0.6× 20 0.1× 333 4.6× 32 0.5× 40 0.8× 26 505

Countries citing papers authored by Kellie L. Jones

Since Specialization
Citations

This map shows the geographic impact of Kellie L. Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kellie L. Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kellie L. Jones more than expected).

Fields of papers citing papers by Kellie L. Jones

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kellie L. Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kellie L. Jones. The network helps show where Kellie L. Jones may publish in the future.

Co-authorship network of co-authors of Kellie L. Jones

This figure shows the co-authorship network connecting the top 25 collaborators of Kellie L. Jones. A scholar is included among the top collaborators of Kellie L. Jones based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kellie L. Jones. Kellie L. Jones is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Jones, Kellie L., et al.. (2011). Clinical outcomes of a pharmacist-managed anticoagulation service for breast cancer patients. Journal of Oncology Pharmacy Practice. 18(1). 122–127. 9 indexed citations
2.
Jones, Kellie L., et al.. (2009). Approaches for Administering Chemotherapy in the Intensive Care Unit. Current Drug Safety. 5(1). 22–32. 5 indexed citations
3.
Jones, Kellie L. & Aman U. Buzdar. (2009). Evolving novel anti-HER2 strategies. The Lancet Oncology. 10(12). 1179–1187. 87 indexed citations
5.
Jones, Kellie L., Charlotte C. Sun, Michael W. Bevers, et al.. (2008). Comparison of chemotherapy education and patient preferences in community versus academic gynecology oncology clinicsa. Journal of Oncology Pharmacy Practice. 14(1). 31–36. 2 indexed citations
6.
Michaud, Laura Boehnke, et al.. (2007). Dietary supplements in patients with cancer: Risks and key concepts, part 1. American Journal of Health-System Pharmacy. 64(4). 369–381. 13 indexed citations
7.
Michaud, Laura Boehnke, et al.. (2007). Dietary supplements in patients with cancer: Risks and key concepts, part 2. American Journal of Health-System Pharmacy. 64(5). 467–480. 7 indexed citations
8.
Jones, Kellie L. & Aman U. Buzdar. (2004). A review of adjuvant hormonal therapy in breast cancer. Endocrine Related Cancer. 11(3). 391–406. 47 indexed citations
9.
Palmer, J. Lynn, Laura Boehnke Michaud, Kellie L. Jones, et al.. (2004). An Assessment of the Utilization of Complementary and Alternative Medication in Women With Gynecologic or Breast Malignancies. Journal of Clinical Oncology. 22(4). 671–677. 149 indexed citations
10.
Jones, Kellie L.. (2003). MEN-10755. Menarini.. PubMed. 4(12). 1473–8. 1 indexed citations
11.
Jones, Kellie L. & Vicente Valero. (2003). Capecitabine‐Induced Pancreatitis. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 23(8). 1076–1078. 22 indexed citations
12.
Michaud, Laura Boehnke & Kellie L. Jones. (2002). Recent Advances in the Systemic Management of Metastatic Breast Cancer. Journal of Pharmacy Practice. 15(1). 52–61. 2 indexed citations
13.
Michaud, Laura Boehnke, Kellie L. Jones, & Aman U. Buzdar. (2001). Combination Endocrine Therapy in the Management of Breast Cancer. The Oncologist. 6(6). 538–546. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026